Tech Center 1600 • Art Units: 1626
This examiner grants 76% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18025853 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | Non-Final OA | Genzyme Corporation |
| 18303802 | COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS | Non-Final OA | Hoffmann-La Roche Inc. |
| 17434672 | COMPOUNDS FOR TARGETED THERAPIES OF CASTRATION RESISTANT PROSTATE CANCER | Non-Final OA | Purdue Research Foundation |
| 18249401 | BIPHENYL PYRROLIDINE AND BIPHENYL DIHYDROIMIDAZOLE DERIVATIVES FOR INHIBITING ACTIVITY OF 5-HT7 SEROTONIN RECEPTOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Non-Final OA | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18548356 | (METH)ACRYLATES CONTAINING A 4-THIAZOLIDINONE UNIT AND POLYMERS THEREOF | Non-Final OA | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN |
| 18548366 | MONOMERS CONTAINING A 4-THIAZOLIDINONE UNIT AND THEIR POLYAMIDE, POLYESTER AND POLYURETHANE POLYCONDENSATES | Non-Final OA | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN |
| 18022677 | METHODS AND MATERIALS FOR INCREASING NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE ACTIVITY | Final Rejection | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18548348 | BENZOXAZOLONE INHIBITORS OF INFLAMMASOMES | Non-Final OA | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS |
| 17429259 | COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USE THEREOF | Non-Final OA | Schedule 1 Therapeutics, Inc. |
| 18578744 | METHODS OF TREATING NEPHROTIC SYNDROME | Non-Final OA | The Research Institute at Nationwide Children's Hospital |
| 18579213 | PHARMACEUTICALLY ACCEPTABLE SALT OF MOR RECEPTOR AGONIST, AND POLYMORPH THEREOF AND USE THEREOF | Non-Final OA | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. |
| 18559682 | Polymorph Of Imidazolidinone Compound, Preparation Method Therefor And Use Thereof | Non-Final OA | Betta Pharmaceuticals Co., Ltd. |
| 18548119 | NOVEL PROCESS FOR THE PREPARATION OF 2,5-DICHLORO-3-(5-(3,4-DIHYDROXY-5-NITROPHENYL)-1,2,4-OXADIAZOL-3-YL)-4,6-DIMETHYLPYRIDINE-1-OXIDE | Non-Final OA | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER |
| 18282279 | THERAPEUTIC REGIMENS OF AN INHIBITOR OF THE ENZYMATIC ACTIVITY OF BRG1 AND BRM | Non-Final OA | FOGHORN THERAPEUTICS INC. |
| 18564291 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Non-Final OA | Schrödinger, Inc. |
| 18552784 | PREPARATION METHOD FOR BICYCLIC COMPOUND AND APPLICATION AS ANTIFUNGAL AGENT | Non-Final OA | JIANGXI JEMINCARE GROUP CO., LTD |
| 18262712 | TRIAZINE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | Athos Therapeutics, Inc. |
| 18279465 | TREATMENT AND/OR REDUCTION OF OCCURRENCE OF MIGRAINE | Non-Final OA | CGRP Diagnostics GmbH |
| 18258418 | KCNT1 INHIBITORS AND METHODS OF USE | Non-Final OA | Praxis Precision Medicines, Inc. |
| 18264073 | AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Non-Final OA | SHANGHAI BLUERAY BIOPHARMA CO., LTD. |
| 18271924 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | Final Rejection | Chengdu Anticancer Bioscience LTD |
| 17764285 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | Non-Final OA | Newave Pharmaceutical Inc. |
| 18267643 | SMAC MIMETICS FOR TREATMENT OF CANCER, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF | Final Rejection | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH |
| 18252024 | METHODS FOR DISRUPTING MITOCHONDRIAL UNFOLDED PROTEIN RESPONSE | Non-Final OA | Health Research, Inc. |
| 18023270 | COMPOUNDS AND METHODS OF USE | Non-Final OA | Ferro Therapeutics, Inc |
| 18022439 | TETRACYCLIC DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF IN MEDICINE | Final Rejection | SHANGHAI ARYL PHARMTECH CO., LTD. |
| 18006830 | CARBALDEHYDE OXIMES AS BUTYRYLCHOLINESTERASE REACTIVATORS | Final Rejection | INSTITUT NATIONAL DES SCIENCES APPLIQUÉES DE ROUEN |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy